Agios Pharmaceuticals (AGIO) stock price, revenue, and financials

Agios Pharmaceuticals market cap is $2.3 b, and annual revenue was $203.2 m in FY 2020

$2.3 B

AGIO Mkt cap, 12-Nov-2021
Agios Pharmaceuticals Net income (Q1, 2021)1.9 B
Agios Pharmaceuticals EBIT (Q1, 2021)-91.2 M
Agios Pharmaceuticals Cash, 31-Mar-20211.9 B
Agios Pharmaceuticals EV539.7 M
Get notified regarding key financial metrics and revenue changes at Agios PharmaceuticalsLearn more
Banner background

Agios Pharmaceuticals Income Statement

Agios Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

71.6m14.0m71.8m160.8m102.7m70.5m80.9m127.4m

Accounts Receivable

2.3m3.4m600.0k169.0k5.1m

Prepaid Expenses

2.5m4.8m8.7m17.5m24.2m23.7m

Inventories

10.3m869.0k7.3m14.7m

Current Assets

169.7m359.5m337.3m559.9m445.3m613.8m611.7m636.7m

PP&E

3.8m6.4m23.2m25.3m24.4m24.3m31.5m32.3m

Total Assets

201.2m491.9m420.1m619.1m614.4m858.5m890.7m853.0m

Accounts Payable

3.7m11.1m14.7m17.1m22.8m17.9m21.9m26.8m

Dividends Payable

Short-term debt

7.1m

Current Liabilities

36.9m61.1m52.9m88.4m94.9m93.5m92.9m94.4m

Long-term debt

106.7m97.8m

Total Debt

106.7m104.9m

Total Liabilities

238.9m170.9m250.2m453.5m

Common Stock

31.0k37.0k38.0k49.0k68.0k69.0k

Preferred Stock

Additional Paid-in Capital

244.9m591.3m630.1m842.0m1.2b1.8b2.2b2.2b

Retained Earnings

(113.4m)(166.9m)(284.7m)(483.2m)(798.1m)(1.1b)(1.5b)(1.8b)

Total Equity

131.5m424.4m345.1m358.6m375.5m687.5m640.5m399.5m

Financial Leverage

1.5 x1.2 x1.2 x1.7 x1.6 x1.2 x1.4 x2.1 x

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

77.5m106.0m32.8m108.2m70.0m35.3m72.5m80.0m39.0m234.0m285.5m200.3m138.7m132.7m364.5m210.3m156.5m103.4m83.6m81.7m89.1m295.9m104.9m1.9b

Accounts Receivable

6.9m5.3m3.0m571.0k2.0m3.4m3.5m779.0k859.0k2.6m

Prepaid Expenses

2.0m2.6m3.0m2.8m5.0m5.5m4.6m7.2m9.2m8.9m10.3m12.4m13.0m15.3m15.6m19.7m19.1m20.0m29.2m27.0m28.9m19.5m

Inventories

863.0k2.3m4.7m5.8m9.8m11.2m11.4m

Current Assets

102.5m198.8m172.4m245.2m247.6m364.1m390.2m371.7m329.5m484.2m600.9m506.9m604.7m528.3m803.0m753.8m695.5m557.1m533.7m490.1m587.3m846.4m669.1m2.4b

PP&E

3.8m3.6m3.5m3.2m3.7m14.3m19.3m21.1m23.0m25.1m26.3m24.1m24.8m24.0m23.7m24.1m24.6m24.0m23.0m24.1m33.8m33.9m33.5m29.0m

Total Assets

111.3m219.1m181.9m272.0m269.6m474.3m474.4m449.1m396.1m557.6m672.0m557.3m760.6m687.2m1.0b998.2m929.1m822.1m783.9m698.6m799.7m976.1m908.4m2.5b

Accounts Payable

3.0m2.1m4.4m5.4m6.2m12.6m8.9m9.0m13.7m18.4m15.4m16.2m23.4m17.9m17.9m17.3m16.6m12.4m15.4m21.5m18.7m15.5m12.9m51.2m

Short-term debt

6.5m6.7m6.9m8.0m

Current Liabilities

37.0m37.4m34.1m44.6m35.1m36.4m45.2m49.8m45.1m67.3m78.0m82.4m93.6m88.1m74.7m84.9m84.7m80.9m89.5m92.4m69.9m64.4m69.8m96.5m

Long-term debt

66.0m110.1m108.1m104.0m101.9m100.1m95.3m

Total Debt

66.0m110.1m108.1m110.5m108.5m107.0m103.3m

Total Liabilities

251.6m237.4m174.5m175.1m168.9m201.9m251.2m250.3m174.4m417.7m428.0m191.8m

Common Stock

4.0k31.0k32.0k34.0k35.0k37.0k37.0k38.0k38.0k38.0k42.0k42.0k48.0k49.0k58.0k59.0k59.0k59.0k69.0k69.0k69.0k70.0k

Preferred Stock

Additional Paid-in Capital

2.8m243.6m247.0m344.5m347.9m598.5m607.7m619.5m640.1m652.6m828.0m857.1m1.1b1.2b1.7b1.7b1.8b1.8b1.8b1.9b2.2b2.2b2.2b2.3b

Retained Earnings

(89.9m)(101.1m)(125.7m)(144.0m)(140.3m)(171.9m)(203.8m)(244.1m)(307.9m)(363.8m)(426.7m)(549.6m)(632.6m)(709.8m)(849.4m)(918.2m)(1.0b)(1.2b)(1.3b)(1.4b)(1.6b)(1.6b)(1.7b)30.9m

Total Equity

(87.0m)142.6m121.3m200.5m207.7m426.8m404.2m375.7m332.4m289.1m401.4m307.4m509.0m449.8m865.6m823.1m760.2m620.3m532.7m448.3m625.3m558.5m480.5m2.3b

Financial Leverage

-1.3 x1.5 x1.5 x1.4 x1.3 x1.1 x1.2 x1.2 x1.2 x1.9 x1.7 x1.8 x1.5 x1.5 x1.2 x1.2 x1.2 x1.3 x1.5 x1.6 x1.3 x1.7 x1.9 x1.1 x

Agios Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(39.4m)(53.5m)(117.7m)(198.5m)(314.7m)(346.0m)(411.5m)(327.4m)

Depreciation and Amortization

1.4m1.4m3.3m5.7m6.4m7.2m8.1m10.0m

Accounts Receivable

(2.3m)(1.0m)275.0k2.9m

Inventories

(869.0k)(6.5m)(7.4m)

Accounts Payable

30.0k7.6m4.2m3.5m5.3m(5.5m)3.7m5.9m

Cash From Operating Activities

(56.4m)(59.4m)(76.9m)38.6m(285.2m)(304.4m)(370.6m)(290.8m)

Purchases of PP&E

(1.3m)(2.2m)(20.2m)(9.9m)(4.6m)(7.0m)(12.2m)(14.9m)

Cash From Investing Activities

(87.2m)(333.3m)128.3m(119.3m)(57.9m)(273.8m)91.4m75.7m

Long-term Borrowings

(113.0k)(336.0k)

Cash From Financing Activities

123.9m335.2m6.4m169.8m285.1m546.0m289.6m261.5m

Net Change in Cash

(19.7m)(57.5m)57.7m89.0m(58.0m)(32.2m)10.4m46.5m

Income Taxes Paid

6.0m

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(15.8m)(27.0m)(12.2m)(30.5m)(26.8m)(5.0m)(36.9m)(77.1m)(23.2m)(79.2m)(142.0m)(66.2m)(149.2m)(226.4m)(90.8m)(159.6m)(254.2m)(93.1m)(202.9m)(309.1m)(40.3m)(130.7m)(229.7m)1.9b

Depreciation and Amortization

723.0k1.1m332.0k659.0k1.0m370.0k1.2m2.2m1.2m2.6m4.0m1.6m3.2m4.8m1.7m3.5m5.3m2.0m4.0m6.1m2.5m4.9m7.3m2.5m

Accounts Receivable

(4.6m)(2.9m)(659.0k)2.8m1.4m271.0k(24.0k)2.6m2.6m

Inventories

(863.0k)(1.5m)(3.8m)(5.0m)(2.4m)(3.9m)(4.0m)

Accounts Payable

(271.0k)(1.2m)720.0k1.7m2.4m(2.7m)(1.2m)(1.3m)(293.0k)3.8m1.7m(994.0k)4.9m742.0k(4.5m)(6.2m)(5.8m)(4.9m)(1.9m)2.6m(2.0m)(7.5m)(7.6m)(2.9m)

Cash From Operating Activities

(27.8m)(42.8m)(27.0m)(28.1m)(51.6m)(25.6m)(21.6m)(46.4m)(19.0m)138.8m89.8m(74.1m)(133.1m)(210.8m)(99.0m)(166.4m)(230.2m)(103.3m)(191.4m)(277.0m)(105.4m)(173.2m)(241.4m)(120.7m)

Purchases of PP&E

(976.0k)(1.1m)(13.0k)(99.0k)(727.0k)(3.8m)(14.7m)(18.0m)(2.5m)(5.3m)(8.7m)(293.0k)(1.3m)(3.3m)(1.4m)(2.8m)(5.9m)(2.0m)(3.3m)(5.3m)(4.5m)(8.7m)(13.9m)(1.0m)

Cash From Investing Activities

13.9m(66.8m)(12.3m)(30.9m)(46.0m)45.0m77.2m107.4m(14.8m)20.9m(41.8m)109.6m(166.2m)(99.8m)(167.5m)(263.8m)(261.0m)131.4m195.8m276.2m108.1m130.6m4.4m1.9b

Long-term Borrowings

(80.0k)(166.0k)(250.0k)(86.0k)

Cash From Financing Activities

72.0k124.3m582.0k95.7m96.1m1.8m2.9m5.1m1.1m2.6m165.8m4.0m277.2m282.5m528.3m537.8m545.0m4.9m8.7m12.0m5.4m257.5m260.9m7.3m

Net Change in Cash

(13.8m)14.7m(38.7m)36.7m(1.5m)21.2m58.5m66.0m(32.7m)162.3m213.7m39.5m(22.0m)(28.0m)261.7m107.6m53.8m32.9m13.1m11.2m8.2m214.9m23.9m1.8b

Income Taxes Paid

289.0k6.0m6.0m6.0m

Agios Pharmaceuticals Ratios

USDQ2, 2013

Financial Leverage

-1.3 x

Agios Pharmaceuticals Employee Rating

4.279 votes
Culture & Values
4.4
Work/Life Balance
4.5
Senior Management
4.3
Salary & Benefits
4.4
Career Opportunities
4.1
Source